Stock Taper
SCREENER COMPARE ANY 2 STOCKS
MESO
MESOBLAST LIMITED
NASDAQ
$17.44
▼ DOWN 4.07% (-0.74)

KEY STATISTICS

Market Cap$2.26 B
52w High$21.50
52w Low$12.66
Dividend Yield—
Frequency—
P/E-13.69
Volume234.68K
Shares Out.129.70M

COMPANY

LEADERSHIP

Silviu Itescu
CHIEF EXECUTIVE
Silviu Itescu

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 20, 2010
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
108

PRICE TARGET

Target High$39.00
Target Low$39.00
Target Median$39.00
Target Consensus$39.00

UPCOMING EARNINGS

DateMar 4, 2027
DayThursday
Rev. Est.$87.89M
MAR
4
THU

SPLIT RECORD

DATETYPERATIO
2024-01-10Reverse1:2
2023-12-05Forward529:500
2017-08-29Forward1011:1000

PRICE

$17.44 ▼ DOWN 4.07% (−$0.74)
OVERLAYS
$17.40$17.60$17.80$18.009:31 AM10:36 AM11:40 AM12:45 PM1:50 PM2:54 PM3:59 PM17.44

About Mesoblast Limited

https://www.mesoblast.com ↗

Mesoblast Limited is a biopharmaceutical company developing allogeneic cellular medicines using mesenchymal cells for various conditions, with products in clinical trials and strategic partnerships worldwide.

INDUSTRY

Biotechnology

A PRODUCT MESOBLAST LIMITED IS KNOWN FOR

RYONCIL® (remestemcel-L)
RYONCIL® (remestemcel-L)

Mesoblast's FDA-approved allogeneic cellular therapy treats steroid-refractory acute graft-versus-host disease in children, marking its first commercial product from its proprietary mesenchymal cell platform.

COMPETITORS

COMPETITOR
INCY COMPARE
PLUR COMPARE
SNY COMPARE
VRTX COMPARE

Revenue by Geography

MapREGIONFY2020
AUSTRALIA$20M

ETFS HOLDING THIS STOCK

ETFS HOLDING
12
LISTED HERE
5
RANKED BY POSITION SIZE
IBB
0.08% · 525.5K
APIE
0.01% · 8.8K
QQQS
0.57% · 7.3K
BIB
0.03% · 1.9K
XGEN.L
0.26% · 1.7K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
3.05%
HOLDERS
103
TOP 12 OF 103 · RANKED BY POSITION SIZE
Legal & General Group Plc
679.0K sh · $12.24M
Blackrock, Inc.
676.4K sh · $12.2M
Morgan Stanley
597.0K sh · $10.77M
Susquehanna International Group, Llp
429.8K sh · $7.75M
Goldman Sachs Group Inc
407.3K sh · $6.56M
Srs Capital Advisors, Inc.
200.1K sh · $3.23M
Summit X, LLC
199.3K sh · $2.17M
Ubs Group AG
187.2K sh · $3.02M
Jane Street Group, LLC
167.4K sh · $3.02M
Ronit Capital Llp
150.0K sh · $382K
Princeton Capital Management Inc
133.4K sh · $731K
Citadel Advisors LLC
131.4K sh · $2.37M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
OBRIEN JAMES MICHAEL
Purchase · 650.0K shares
2025-12-23
★
DIRECTOR
COBLEY LYNETTE ELIZABETH
— · —
2026-03-18
★
DIRECTOR
COBLEY LYNETTE ELIZABETH
— · 200.0K shares
2026-03-18
★
DIRECTOR, 10 PERCENT OWNER:
George Gregory
Purchase · 10.0K shares
2026-04-09

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
Jefferies BUY

SECTORS PEERS

PEERPRICE
IBRX$8.05COMPARE
LQDA$67.69COMPARE
COGT$34.67COMPARE
EWTX$42.76COMPARE
QURE$48.72COMPARE
GPCR$47.37COMPARE
VRDN$23.08COMPARE
NUVB$6.66COMPARE